Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose

Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM

J Clin Endocrinol Metab.

Al Jobori H, Daniele G, Adams J, Cersosimo E, Solis-Herrera C, Triplitt C, DeFronzo RA, Abdul-Ghani M

doi: 10.1210/jc.2017-01838.

Type 2 Diabetes

Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study

Diabetes Obes Metab.

Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T

doi: 10.1111/dom.14189.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

JAMA Intern Med.

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC

doi: 10.1001/jamainternmed.

Glycemic Control

The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis

Nutr Metab Cardiovasc Dis

Bai Y, Jin J, Zhou W, Zhang S, Xu J

doi: 10.1016/j.numecd.2021.02.006

COMMENTED

Diabetes - GeneralType 1 Diabetes

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables

Diabetologia.

Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC; Type 1 Diabetes TrialNet Study Group; Immune Tolerance Network Study Group

doi: 10.1007/s00125-018-4722-z.

Diabetes - GeneralGlycemic Control

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis

J Am Heart Assoc.

Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL

doi: 10.1161/JAHA.117.005686.

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index

Diabetes Metab Res Rev.

Bonadonna RC, Blonde L, Antsiferov M, Berria R, Gourdy P, Hatunic M, Mohan V, Horowitz M

doi: 10.1002/dmrr.2897.

COMMENTED

Type 2 Diabetes

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

BMJ.

Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B

doi: 10.1136/bmj.k4365.

Related content

Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM

Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study